biosimilars

CEO Richard Saynor

Sandoz signed a Memorandum of Understanding (MOU) to build a new biologics production plant in Lendava, Slovenia. The investment is expected to be at least $400 million, supporting the company’s ambition to drive the future growth of its global biosimilars portfolio. This represents one of the largest-ever...